In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
Sign Up to like & getrecommendations! Published in 2024 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwae254
Abstract: INTRODUCTION Inclisiran, an siRNA targeting hepatic PCSK9 mRNA, administered twice-yearly (after initial and 3-month doses), substantially and sustainably reduced LDL-cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a reduced risk… read more here.
Keywords: sirius programme; trial; silico trial; inclisiran ... See more keywords